Apricus Biosciences, Inc. (Nasdaq: APRI) announced the pricing of an underwritten public offering of an aggregate of 5,030,000 units, with ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE